EUVIMEDEUVIMED entdecken
Multizentrische Studie

Anti‐Tumor Activity of Paclitaxel‐Containing Regimens in Recurrent/Refractory Wilms Tumor

Alissa Groisser iD, Amy Frantz, James I Geller iD, Michael V Ortiz iD, David Walterhouse, Mark Ranalli, Wendy Woods-Swafford, Peter Schoettler, Timothy Garrington iD, Elizabeth A Mullen, Shifra Ash, Pooja Bardhan und 2 weitere

Pediatric Blood & Cancer · 2025

DOI: 10.1002/pbc.31915 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Pediatric Blood & Cancer, 2025. Verfasst von Alissa Groisser und 13 weiteren Autor:innen. Beteiligte Einrichtung: Center For Cancer and Blood Disorders, Children's National Hospital and the Department of Pediatrics, George Washington University School of Medicine…. Hauptthemen laut MEDLINE: Wilms Tumor, Paclitaxel, Kidney Neoplasms, Neoplasm Recurrence, Local. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 37 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The Pediatric Oncology Group P9262 Phase 2 study of single‐agent paclitaxel demonstrated one complete response (CR), one partial response (PR), and four with stable disease (SD) among 15 patients with recurrent Wilms tumor (WT). Based on this activity, paclitaxel‐containing regimens have been used as salvage therapy for treatment‐refractory WT. We conducted a multi‐institutional retrospective study to further characterize the clinical activity of paclitaxel‐containing regimens in recurrent WT.

Methods

Twelve institutions submitted anonymized data from patients with relapsed WT treated with paclitaxel. Response after one or two cycles of a paclitaxel‐containing regimen was reported according to Response Evaluation Criteria in Solid Tumors.

Results

Twenty‐eight patients with a median age at diagnosis of 5.5 years (range: 3 months to 31.9 years) were reported. Twenty had non‐anaplastic WT; eight had diffuse anaplasia (DA). Stage at diagnosis was I ( n = 1), II ( n = 1), III ( n = 11), IV ( n = 14), and V ( n = 1). Patients received a mean of 8.5 anticancer drugs (range: 6–12) before paclitaxel, including eight who received high‐dose therapy/stem cell transplant. Paclitaxel ( n = 13) or nab‐paclitaxel ( n = 15) were predominantly administered in combination with other agents, most commonly doxorubicin and/or gemcitabine. Eleven of 26 patients with measurable disease had a partial response (7 = non‐anaplastic; 4 = DA), four had stable disease, and 11 had progressive disease. Two patients without measurable disease maintained a complete response for 12 and 16 months. The mean duration without progression was 7.6 months (range: 1–35 months).

Conclusions

Paclitaxel‐containing regimens appear to be active against heavily pretreated WT with either non‐anaplastic or DA histology. Prospective studies are warranted to formally evaluate the efficacy of paclitaxel‐based therapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Wilms TumorPaclitaxelKidney NeoplasmsNeoplasm Recurrence, LocalAntineoplastic Combined Chemotherapy ProtocolsHumansChild, PreschoolChildInfantMaleFemaleAdolescentRetrospective StudiesAdultYoung AdultSalvage TherapyAntineoplastic Agents, Phytogenic

Stichwörter der Autor:innen

Wilms tumornephroblastomapaclitaxelrecurrentrelapsetaxane

Substanzen

PaclitaxelAntineoplastic Agents, Phytogenic

Autor:innen und Institutionen

  • Center For Cancer and Blood Disorders, Children's National Hospital and the Department of Pediatrics, George Washington University School of Medicine and Health Sciences, Washington, District of Columbia, USA.
  • Division of Oncology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.
  • Memorial Sloan Kettering Cancer Center, New York, New York, USA.
  • Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, USA.
  • Nationwide Children's Hospital, Columbus, Ohio, USA.
  • Blank Cancer and Blood Disorders Center, Blank Children's Hospital-UnityPoint Health, Des Moines, Iowa, USA.

ORCID-Profile: Alissa Groisser, James I Geller, Michael V Ortiz, Timothy Garrington, Jeffrey S Dome

Zitieren

APA

Groisser, A., Frantz, A., Geller, J. I., Ortiz, M. V., Walterhouse, D., Ranalli, M., Woods-Swafford, W., Schoettler, P., Garrington, T., Mullen, E. A., Ash, S., Bardhan, P., Balis, F., & Dome, J. S. (2025). Anti‐Tumor Activity of Paclitaxel‐Containing Regimens in Recurrent/Refractory Wilms Tumor. Pediatric Blood & Cancer. https://doi.org/10.1002/pbc.31915

Vancouver

Groisser A, Frantz A, Geller JI, Ortiz MV, Walterhouse D, Ranalli M, et al. Anti‐Tumor Activity of Paclitaxel‐Containing Regimens in Recurrent/Refractory Wilms Tumor. Pediatric Blood & Cancer. 2025. doi:10.1002/pbc.31915

BibTeX
@article{Groisser2025,
  author = {Groisser, Alissa and Frantz, Amy and Geller, James I and Ortiz, Michael V and Walterhouse, David and Ranalli, Mark and Woods-Swafford, Wendy and Schoettler, Peter and Garrington, Timothy and Mullen, Elizabeth A and Ash, Shifra and Bardhan, Pooja and Balis, Frank and Dome, Jeffrey S},
  title = {Anti‐Tumor Activity of Paclitaxel‐Containing Regimens in Recurrent/Refractory Wilms Tumor},
  journal = {Pediatric Blood & Cancer},
  year = {2025},
  doi = {10.1002/pbc.31915}
}
Kostenlos starten →